Genexine Inc
Genexine, Inc., together with its subsidiaries, operates as a biotechnology company that focuses on the development and commercialization of immunotherapies in South Korea and internationally. The company develops its products through its hybrid Fc platform, a proprietary technology designed to develop long-acting protein drugs; and the DNA vaccine platform that is used to elicit immune responses… Read more
Genexine Inc (095700) - Net Assets
Latest net assets as of September 2025: ₩260.01 Billion KRW
Based on the latest financial reports, Genexine Inc (095700) has net assets worth ₩260.01 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩366.23 Billion) and total liabilities (₩106.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩260.01 Billion |
| % of Total Assets | 71.0% |
| Annual Growth Rate | 13.63% |
| 5-Year Change | -51.14% |
| 10-Year Change | 108.07% |
| Growth Volatility | 73.29 |
Genexine Inc - Net Assets Trend (2009–2024)
This chart illustrates how Genexine Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Genexine Inc (2009–2024)
The table below shows the annual net assets of Genexine Inc from 2009 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩261.68 Billion | -11.86% |
| 2023-12-31 | ₩296.90 Billion | +7.51% |
| 2022-12-31 | ₩276.15 Billion | -46.66% |
| 2021-12-31 | ₩517.74 Billion | -3.34% |
| 2020-12-31 | ₩535.60 Billion | +80.39% |
| 2019-12-31 | ₩296.91 Billion | -7.36% |
| 2018-12-31 | ₩320.51 Billion | +181.37% |
| 2017-12-31 | ₩113.91 Billion | -33.09% |
| 2016-12-31 | ₩170.24 Billion | +35.37% |
| 2015-12-31 | ₩125.77 Billion | +174.45% |
| 2012-12-31 | ₩45.83 Billion | +90.60% |
| 2011-12-31 | ₩24.04 Billion | -9.04% |
| 2010-12-31 | ₩26.43 Billion | -31.35% |
| 2009-12-31 | ₩38.50 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Genexine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10847953595400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩22.77 Billion | 8.70% |
| Other Components | ₩348.28 Billion | 133.09% |
| Total Equity | ₩261.68 Billion | 100.00% |
Genexine Inc Competitors by Market Cap
The table below lists competitors of Genexine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
JADESTONE ENERGY LS -001
F:8KW
|
$111.46 Million |
|
Eugene Corporation
KQ:023410
|
$111.46 Million |
|
Wendell Industrial Co. Ltd
TWO:6761
|
$111.51 Million |
|
Bank Bukopin Tbk
JK:BBKP
|
$111.65 Million |
|
Chinese Maritime Transport Ltd
TW:2612
|
$111.34 Million |
|
G8 Education Ltd
AU:GEM
|
$111.33 Million |
|
Loncor Resources Inc
TO:LN
|
$111.32 Million |
|
Shining Building Business Co Ltd
TW:5531
|
$111.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genexine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 296,621,808,460 to 261,680,674,540, a change of -34,941,133,920 (-11.8%).
- Net loss of 63,705,874,580 reduced equity.
- Other factors increased equity by 28,764,740,660.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-63.71 Billion | -24.34% |
| Other Changes | ₩28.76 Billion | +10.99% |
| Total Change | ₩- | -11.78% |
Book Value vs Market Value Analysis
This analysis compares Genexine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.69x to 0.84x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩6939.66 | ₩4815.00 | x |
| 2017-12-31 | ₩4116.46 | ₩4815.00 | x |
| 2018-12-31 | ₩11378.19 | ₩4815.00 | x |
| 2019-12-31 | ₩12495.50 | ₩4815.00 | x |
| 2020-12-31 | ₩21686.37 | ₩4815.00 | x |
| 2021-12-31 | ₩15000.68 | ₩4815.00 | x |
| 2022-12-31 | ₩8448.05 | ₩4815.00 | x |
| 2023-12-31 | ₩7156.17 | ₩4815.00 | x |
| 2024-12-31 | ₩5753.79 | ₩4815.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genexine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.34%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -2172.23%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.32x
- Recent ROE (-24.34%) is below the historical average (-12.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -1.28% | -46.16% | 0.02x | 1.11x | ₩-4.34 Billion |
| 2010 | -17.81% | -436.26% | 0.03x | 1.43x | ₩-7.35 Billion |
| 2011 | -29.15% | -265.05% | 0.07x | 1.62x | ₩-9.47 Billion |
| 2012 | -4.57% | -33.53% | 0.10x | 1.38x | ₩-6.68 Billion |
| 2015 | -1.13% | -4.39% | 0.23x | 1.13x | ₩-14.00 Billion |
| 2016 | -18.17% | -272.49% | 0.06x | 1.17x | ₩-47.96 Billion |
| 2017 | -16.97% | -67.93% | 0.20x | 1.24x | ₩-30.72 Billion |
| 2018 | -10.63% | -264.46% | 0.03x | 1.17x | ₩-66.12 Billion |
| 2019 | -5.56% | -146.06% | 0.03x | 1.21x | ₩-46.20 Billion |
| 2020 | 5.15% | 148.68% | 0.03x | 1.11x | ₩-25.99 Billion |
| 2021 | -9.22% | -129.59% | 0.06x | 1.23x | ₩-99.50 Billion |
| 2022 | -20.38% | -348.69% | 0.04x | 1.41x | ₩-83.89 Billion |
| 2023 | -22.55% | -1510.71% | 0.01x | 1.27x | ₩-96.54 Billion |
| 2024 | -24.34% | -2172.23% | 0.01x | 1.32x | ₩-89.87 Billion |
Industry Comparison
This section compares Genexine Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genexine Inc (095700) | ₩260.01 Billion | -1.28% | 0.41x | $111.37 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |